Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AstraZeneca

UK fuel retailers accused of ‘ripping off’ motorists at the pumps; markets shrug off latest Trump tariffs – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK

UK is ‘worst country in Europe’ for drug prices, says Mounjaro maker

Eli Lilly CEO says Britain’s strict regime means it could miss out on new drugs being rolled out unless it pays more

The Guardian - UK

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

AstraZeneca Plc (NASDAQ:AZN) released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).

Benzinga

UK set on resolving standoff with big pharma, science minister says

Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investment

The Guardian - UK

UK ‘difficult’ operating environment says Merck boss after £1bn London site axed

Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.

Evening Standard

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

The Guardian view on Merck’s exit: Britain’s biopharma strategy stalls in the face of China’s rise

Editorial: The industry’s retreat from the UK reflects a deeper shift about how Beijing is rewriting the rules of innovation

The Guardian - UK

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

Benzinga

AstraZeneca pauses £200m expansion in Cambridge

It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year.

Evening Standard

Britain’s biggest company AstraZeneca pauses £200m investment into Cambridge site

The investment had been set to create 1,000 jobs

The Independent UK

AstraZeneca pauses £200m investment in Cambridge research site

Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding

The Guardian - UK

Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister

The Conservatives said Merck’s decision should send alarm bells ringing across Government.

Evening Standard

FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer

On Wednesday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Koselugo (selumetinib) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), benign, nerve sheath tumors.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study

On Sunday, AstraZeneca Plc (AZN) released results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial in previously untreated patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletion or exon 21 L858R mutations.

Benzinga

AstraZeneca, Corning And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his final trade.

Benzinga

AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure

On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the BaxHTN Phase 3 trial evaluating baxdrostat. The company released the topline data in July.

The Independent UK

New blood pressure pill ‘lowers risk of heart problems in 12 weeks’

IN FULL

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

The new daily pill that lowers high blood pressure by ‘spectacular’ amounts

Baxdrostat, developed by AstraZeneca, could help 10 million people worldwide

The Independent UK

New daily pill offers hope for millions with hard to control high blood pressure

A phase III trial of Baxdrostat showed it significantly lowered blood pressure in patients whose levels remained high despite being on other drugs.

The Guardian - UK

Wes Streeting’s row with pharma firms grows as they reject NHS drug pricing offer

Drugmakers reject health secretary’s latest offer, meaning ‘unsustainable’ rebate scheme will stay in place

Benzinga

J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

International Business Times UK

EuroMillions Result: 5 Stocks the £210M Lottery Winner Could Consider

French ticket-holder wins £210M EuroMillions on 19 Aug 2025, beating UK records. Grow wealth with AstraZeneca, Unilever, Shell, Microsoft, HSBC

The Independent UK

Top executives’ pay in UK hits record high – reaching 122 times of average worker

It marks the fourth year in a row that chief executives have taken home a record amount

Evening Standard

Top executive pay in UK’s biggest firms hits new record as more take home £10m

Median pay for chief executive officers of FTSE 100 companies was £4.58 million in the 2024-2025 financial year.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.